$375 Million is the total value of Octagon Capital Advisors LP's 20 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 38.5% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
STOK | Sell | STOKE THERAPEUTICS INC | $10,085,000 | -41.1% | 763,456 | -6.1% | 2.69% | -27.3% |
BBIO | Sell | BRIDGEBIO PHARMA INC | $8,478,000 | -63.2% | 933,743 | -58.8% | 2.26% | -54.5% |
FDMT | Sell | 4D MOLECULAR THERAPEUTICS IN | $4,417,000 | -81.4% | 632,745 | -59.6% | 1.18% | -77.0% |
KROS | Sell | KEROS THERAPEUTICS INC | $4,207,000 | -77.3% | 152,249 | -55.2% | 1.12% | -71.9% |
IMVT | Sell | IMMUNOVANT INC | $2,258,000 | -72.2% | 579,061 | -60.7% | 0.60% | -65.7% |
IMAB | Sell | I MABsponsored ads | $2,259,000 | -86.7% | 199,876 | -81.0% | 0.60% | -83.6% |
IPSC | Sell | CENTURY THERAPEUTICS INC | $2,184,000 | -73.6% | 260,000 | -60.5% | 0.58% | -67.5% |
AMAM | Sell | AMBRX BIOPHARMA INCsponsored ads | $325,000 | -47.2% | 122,800 | -17.8% | 0.09% | -34.6% |
CNTB | Exit | CONNECT BIOPHARMA HLDGS LTDads | $0 | – | -279,921 | -100.0% | -0.18% | – |
Exit | OMEGA THERAPEUTICS INC | $0 | – | -176,470 | -100.0% | -0.24% | – | |
DYN | Exit | DYNE THERAPEUTICS INC | $0 | – | -525,284 | -100.0% | -1.10% | – |
SURF | Exit | SURFACE ONCOLOGY INC | $0 | – | -2,300,000 | -100.0% | -1.46% | – |
ITOS | Exit | ITEOS THERAPEUTICS INC | $0 | – | -450,776 | -100.0% | -3.14% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 33.2% |
ARCUS BIOSCIENCES INC | 12 | Q3 2023 | 18.1% |
CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 10.1% |
GOSSAMER BIO INC | 12 | Q3 2023 | 6.2% |
4D MOLECULAR THERAPEUTICS IN | 10 | Q1 2023 | 6.6% |
BRIDGEBIO PHARMA INC | 10 | Q3 2023 | 6.6% |
AVIDITY BIOSCIENCES INC | 10 | Q1 2023 | 3.8% |
VERA THERAPEUTICS INC | 9 | Q2 2023 | 3.5% |
DYNE THERAPEUTICS INC | 9 | Q3 2023 | 3.5% |
STOKE THERAPEUTICS INC | 9 | Q2 2023 | 3.7% |
View Octagon Capital Advisors LP's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-06 |
SC 13G/A | 2024-02-05 |
SC 13G | 2024-02-05 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
SC 13G | 2023-01-25 |
13F-HR | 2022-11-14 |
View Octagon Capital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.